awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35056525-E946E160-4CEE-466D-A92F-5E367DD9E870
Q35056525-E946E160-4CEE-466D-A92F-5E367DD9E870
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35056525-E946E160-4CEE-466D-A92F-5E367DD9E870
Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making
P2860
Q35056525-E946E160-4CEE-466D-A92F-5E367DD9E870
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35056525-E946E160-4CEE-466D-A92F-5E367DD9E870
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
7da9322eb560d64a4f55c0cfce3e9ffdacf17e18
P2860
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr